PEG 3350 Market is predicted to reach USD 3.09 billion at a CAGR of 6.29% during the forecast period 2023-2032

Market Research Future (MRFR) has published on the “Global PEG 3350 Market”.

PEG 3350 market is estimated to register a CAGR of 6.29% during the forecast period of 2023 to 2032.

MRFR recognizes the following companies as the key players in the global PEG 3350 market— Teva Pharmaceutical Industries Ltd (Israel), LGM Pharma (US), McKesson Corporation (US), Sisco Research Laboratories Pvt. Ltd. (India), BASF SE (Germany), Merck KGaA (US), Bayer AG (Germany), Lupin Pharmaceuticals, Inc (India), Breckenridge Pharmaceutical, Inc. (US), and Pendopharm (Canada).

Market Highlights

The global PEG 3350 market is accounted for to register a CAGR of 6.29% during the forecast period and is estimated to reach USD 3.09 billion by 2032.

Developing economies pose an opportunity for the PEG 3350 market as they have a developing R&D sector along with improving healthcare infrastructure, owing to which they are capable of addressing upcoming health challenges. In spite of huge demand, several countries are dependent on imported medicines and other health technologies. Although there is a high disease prevalence rate and requirement for treatment, poor economic conditions lead to the slow growth of the healthcare industry within the developing region.

Furthermore, according to the report published by the Colorectal Cancer in the Arab World, there will be 1.93 million new cases of colon cancer present in Arab counties. Cancer is growing at an alarming pace in Middle East region countries. Similarly, 6,597 cases were registered in Malaysia in 2021. The increasing patient pool offers growth opportunities for manufacturers in the PEG 3350 market to expand their reach in such nations and aid in the growth of the global PEG 3350 market.

The rising prevalence of colon cancer in India and other developing nations, rising number of strategic initiatives, and increasing sedentary lifestyle and physical inactivity are propelling market growth. However, competition from alternatives products is expected to hamper the growth of the global market. Nevertheless, an increasing aging population is projected to create lucrative opportunities for market players.

Access full report @ https://www.marketresearchfuture.com/reports/peg-3350-market-21465

Segment Analysis

The global PEG 3350 market has been segmented based on product type, age, application, and distribution channel.

On the basis of the product type, the market is segmented into powder and bowel preparation kit. The powder segment was attributed to holding the largest market share of over 62.84% in 2022 revenue as estimated by MRFR analysts. This is due to the growing sedentary lifestyles, physical inactivity, and the rising prevalence of colorectal cancer.

Further, we estimate that the market segment would continue to pool in the largest chunk of revenue during the forecast period. It has been identified that the segment market yet witnesses continuous innovations and movements in terms of new product launches.

On the basis of the age, the market is segmented into pediatric, adult, and geriatric. The adult segment is projected to have the largest market share during the forecast period. This is due to the increasing prevalence of colorectal cancer among adults.

On the basis of the application, the market is segmented into constipation and medical tests. and surgery. The medical tests segment are further bifurcated into colonoscopy and barium enema x-ray examination. The constipation segment is projected to have the largest market share during the forecast period. This is due to the rising prevalence of constipation in the developing regions due to unhealthy lifestyles and the fact that patients with chronic diseases experience constipation, physicians & pharmacists.

On the basis of the distribution channel the market is segmented into the online pharmacy, offline pharmacy. The offline pharmacy segment is projected to have the largest market share during the forecast period. This is attributed to the rising surgical procedures associated with the colon and rectum and other colon-related diseases that require medical tests.

Regional Analysis

The global PEG 3350 market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America consists of US and Canada. The Europe PEG 3350 market comprises Germany, France, the UK, Italy, Spain, and the rest of Europe. The PEG 3350 market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The Rest of the world’s PEG 3350 market comprises of Middle East, Africa, and Latin America.

the rising prevalence of colorectal cancer and other diseases such as diabetes, cancer, and neurological disorders are expected to foster North America’s market growth. Moreover, increasing product launches are expected to support market growth.

Moreover, the Europe market has been persistently growing owing to Colorectal cancer is the most common form of cancer in Europe. As per the World Cancer Research Fund International, Hungary had the highest colorectal cancer number, followed by Slovakia in 2020 globally across the region.

Additionally, market factors, such as the increasing colorectal cancer in the region, unhealthy diet and lifestyle habits and increasing colorectal cancer among the Indian population are driving the Asia-Pacific region’s growth.

Furthermore, the rest of the world's patient portal market is divided into the Middle East, Africa, and Latin America. The major factors driving the growth of the PEG 3350 market in the region are the lack of awareness associated with the right diet. In addition, constipation is more likely to develop in patients with an aortic dissection. In 2019, according to the World Heart Federation, more than 1 million deaths were expected due to CVD in sub-Saharan Africa. Moreover, as per the research, colorectal cancer is increasing in the Middle East in young and older adults and causes frequent constipation among children, further fueling the region's market growth.

Key Findings of the Study

• The global PEG 3350 market is expected to reach USD 3.09 billion by 2032, at a CAGR of 6.29% during the forecast period.


• The Asia-Pacific region accounted for the fastest-growing global market, owing to the rising geriatric population, adoption of sedentary lifestyles and physical inactivity, and the rising prevalence of colorectal cancer in the Asia-Pacific region.


• Based on product type, the powder segment was attributed to holding the largest market in 2022, with an approximate market share of around 62.84%.


• Teva Pharmaceutical Industries Ltd (Israel), LGM Pharma (US), McKesson Corporation (US), Sisco Research Laboratories Pvt. Ltd. (India), BASF SE (Germany), Merck KGaA (US ), Bayer AG (Germany), Lupin Pharmaceuticals, Inc (India), Breckenridge Pharmaceutical, Inc. (US), and Pendopharm (Canada) are the key market players.